Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment